Angiotensin-(1-7): A peptide hormone with anti-cancer activity

Current Medicinal Chemistry

Volumn 21, Issue 21, 2014, Pages 2417-2423

  Gallagher, P E ^a   Arter, A L ^a   Deng, G ^a   Tallant, E A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Angiotensin receptor; Angiotensin (1 7); Cancer; Cancer associated fibrosis; Kinase; Mas; Osteoclastogenesis; Phosphatase; Placental growth factor; Tumor microenvironment; Vascular endothelial growth factor

Indexed keywords

ANGIOTENSIN[1-7]; G PROTEIN COUPLED RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANTINEOPLASTIC AGENT; PEPTIDE FRAGMENT; PEPTIDE HORMONE;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; METASTASIS; NONHUMAN; OSTEOCLASTOGENESIS; PEPTIDE SYNTHESIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; NEOPLASMS; PATHOLOGY; SYNTHESIS; VASCULARIZATION;

AMINO ACID SEQUENCE; ANGIOTENSIN I; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; PEPTIDE HORMONES;

EID: 84901912465     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140205133357     Document Type: Article

References (57)

1. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: science and market. Drug Discov. Today, 2010, 15 (1-2), 40-56.
2. Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des., 2013, 81 (1), 136-147.
3. Thundimadathil, J. Cancer treatment using peptides: current therapies and future prospects. J. Amino. Acids, 2012, 2012, 967347.
4. Chappell, M. C.; Pirro, N. T.; Sykes, A.; Ferrario, C. M. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension, 1998, 31 (part 2), 362-367.
5. Campbell, D. J.; Kladis, A.; Duncan, A. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension, 1994, 23, 439-449.
6. Kohara, K.; Brosnihan, K. B.; Ferrario, C. M. Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides, 1993, 14, 883-891.
7. Santos, R. A. S.; Simoes E Silva AC; Maric, C.; Silva, D. M. R.; Machado, R. D.; DuBuhr, I.; Heringer-Walther, S.; Pinheiro, S. V.; Lopes, M. T.; Bader, M.; Mendes, E. P.; Lemos, V. S.; Campagnole-Santos, M. J.; Schultheiss, H.-P.; Speth, R.; Walther, T. Angiotensin-(1-7) is an endogenous ligand for the G proteincoupled receptor mas. Proc. Natl. Acad. Sci.USA., 2003, 100, 8258-8263.
8. Singh, A.; Boyer, J. L.; Der, C. J.; Zohn, I. E. Transformation by a nucleotide-activated P2Y receptor is mediated by activation of Galphai, Galphaq and Rho-dependent signaling pathways. J. Mol. Signal., 2010, 5, 11.
9. Canals, M.; Jenkins, L.; Kellett, E.; Milligan, G. Up-regulation of the angiotensin II type 1 receptor by the Mas proto-oncogene is due to constitutitive activation of Gq/G11 by Mas. J. Biol. Chem., 2006, 281, 16757-16767.
10. Bikkavilli, R. K.; Tsang, S. Y.; Tang, W. M.; Sun, J. X.; Ngai, S. M.; Lee, S. S.; Ko, W. H.; Wise, H.; Cheung, W. T. Identification and characterization of surrogate peptide ligand for orphan G protein-coupled receptor mas using phage-displayed peptide library. Biochem. Pharmacol., 2006, 71 (3), 319-337.
11. Zhang, T.; Li, Z.; Dang, H.; Chen, R.; Liaw, C.; Tran, T. A.; Boatman, P. D.; Connolly, D. T.; Adams, J. W. Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am. J. Physiol Heart Circ. Physiol., 2012, 302 (1), H299-H311.
12. Jaiswal, N.; Tallant, E. A.; Jaiswal, R. K.; Diz, D. I.; Ferrario, C. M. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine smooth muscle cells: subtypes of angiotensin receptors involved. J. Pharm. Exp. Ther., 1993, 265, 664-673.
13. Clark, M. A.; Diz, D. I.; Tallant, E. A. Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension, 2001, 37 (4), 1141-1146.
14. Fasano, O.; Birnbaum, D.; Edlund, L.; Fogh, J.; Wigler, M. New human transforming genes detected by a tumorigenicity assay. Mol. Cell Biol., 1984, 4 (9), 1695-1705.
15. Young, D.; Waitches, G.; Birchmeier, C.; Fasano, O.; Wigler, M. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell, 1986, 45, 711-719.
16. Tallant, E. A.; Chappell, C. M.; Ferrario, C. M.; Gallagher, P. E. Inhibition of MAP kinase activity by angiotensin-(1-7) in vascular smooth muscle cells is mediated by the mas receptor. Hypertension, 2004, 43, 1348.
17. Tallant, E. A.; Ferrario, C. M.; Gallagher, P. E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, 1560-1566.
18. Gallagher, P. E.; Tallant, E. A. Inhibition of lung cancer cell growth by angiotensin-(1-7). Carcinogenesis, 2004, 25, 2045-2052.
19. Krishnan, B.; Torti, F. M.; Gallagher, P. E.; Tallant, E. A. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate, 2013, 73, 60-70.
20. Neo, J. H.; Ager, E. I.; Angus, P. W.; Zhu, J.; Herath, C. B.; Christophi, C. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC. Cancer, 2010, 10, 134.
21. Bernardi, S.; Zennaro, C.; Palmisano, S.; Velkoska, E.; Sabato, N.; Toffoli, B.; Giacomel, G.; Buri, L.; Zanconati, F.; Bellini, G.; Burrell, L. M.; De, M. N.; Fabris, B. Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J. Renin. Angiotensin. Aldosterone. Syst., 2012, 13 (1), 202-209.
22. Menon, J.; Soto-Pantoja, D. R.; Callahan, M. F.; Cline, J. M.; Ferrario, C. M.; Tallant, E. A.; Gallagher, P. E. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res., 2007, 67, 2809-2815.
23. Soto-Pantoja, D. R.; Menon, J.; Gallagher, P. E.; Tallant, E. A. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol. Cancer Ther., 2009, 8 (6), 1676-1683.
24. Cook, K. L.; Metheny-Barlow, L. J.; Tallant, E. A.; Gallagher, P. E. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res., 2010, 70 (21), 8319-8328.
25. Gallagher, P. E.; Cook, K.; Soto-Pantoja, D.; Menon, J.; Tallant, E. A. Angiotensin peptides and lung cancer. Curr. Cancer Drug Targets, 2011, 11 (4), 394-404.
26. Krishnan, B.; Smith, T. L.; Dubey, P.; Zapadka, M. E.; Torti, F. M.; Willingham, M. C.; Tallant, E. A.; Gallagher, P. E. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate, 2013, 73, 71-82.
27. Luque, M.; Martin, P.; Martell, N.; Fernandez, C.; Brosnihan, K. B.; Ferrario, C. M. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J. Hypertens., 1996, 14, 799-805.
28. Brown, J. R.; Dubois, R. N. Cycloxygenase-2 in lung carcinogenesis and chemoprevention. Chest, 2004, 125, 134S-140S.
29. Castelao, J. E.; Bart III, R. D.; DiPerna, C. A.; Sievers, E. M.; Bremmer, R. M. Lung cancer and cyclooxygenase-2. Ann. Thorac. Surg., 2003, 76, 1327-1335.
30. Wang, D.; Dubois, R. N. Prostaglandins and cancer. Gut, 2006, 55, 115-122.
31. van Zandwijk, N. Chemoprevention in lung carcinogenesis - an overview. Eur. J Cancer, 2005, 41, 1990-2002.
32. Rioux N.; Castonguay A. Prevention of NNK-induced lung umorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res., 1998, 58, 5354-5360.
33. Moody, T. W.; Leyton, J.; Zakowicz, H.; Hida, T.; Kang, Y.; Jakowlew, S.; You, L.; Ozbun, L.; Zia, H.; Yougberg, J.; Malkinson, A. Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res., 2001, 21, 1749-1755.
34. Schreinemachers, D. M.; Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 1994, 5, 138-146.
35. Mukherjee D.; Nissen S.E.; Topol E.J. Risk of cardiovascular events associated wih selective COX-2 inhibitors. JAMA, 2001, 286, 954-959.
36. Kucharewicz, I.; Chabielska, E.; Pawlak, D.; Matys, T.; Rolkowski, R.; Buczko, W. The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. J. Renin. Angiotensin. Aldosterone. Syst., 2000, 1 (3), 268-272.
37. Kucharewicz, I.; Pawlak, R.; Matys, T.; Pawlak, D.; Buczko, W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension, 2002, 40 (5), 774-779.
38. Fraga-Silva, R. A.; Sorg, B. S.; Wankhede, M.; deDeugd, C.; Jun, J. Y.; Baker, M. B.; Li, Y.; Castellano, R. K.; Katovich, M. J.; Raizada, M. K.; Ferreira, A. J. ACE2 activation promotes antithrombotic activity. Mol. Med., 2010, 16 (5-6), 210-215.
39. Fraga-Silva, R. A.; Costa-Fraga, F. P.; De Sousa, F. B.; Alenina, N.; Bader, M.; Sinisterra, R. D.; Santos, R. A. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics. (Sao Paulo), 2011, 66 (5), 837-841.
40. Fang, C.; Stavrou, E.; Schmaier, A. A.; Grobe, N.; Morris, M.; Chen, A.; Nieman, M. T.; Adams, G. N.; LaRusch, G.; Zhou, Y.; Bilodeau, M. L.; Mahdi, F.; Warnock, M.; Schmaier, A. H. Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/-mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood, 2013, 121 (15), 3023-3032.
41. Machado, R. D.; Santos, R. A.; Andrade, S. P. Opposing actions of angiotensins on angiogenesis. Life Sci., 2000, 66 (1), 67-76.
42. Machado, R. D. P.; Santos, R. A. S.; Andrade, S. P. Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis. Am. J. Physiol. Regulatory Integrative Comp. Physiol., 2001, 280, 994-1000.
43. Freeman, E. J.; Chisolm, G. M.; Ferrario, C. M.; Tallant, E. A. Angiotenin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension, 1996, 28, 104-108.
44. Strawn, W. B.; Ferrario, C.M.; Tallant, E.A. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension, 1999, 33 (part II), 207-211.
45. Tallant, E. A.; Diz, D. I.; Ferrario, C. M. State-of - The-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension, 1999, 34 (4 Pt 2), 950-957.
46. Zhang, J.; Liu, J. Tumor stroma as targets for cancer therapy. Pharmacol. Ther., 2013, 137 (2), 200-215.
47. Sounni, N. E.; Noel, A. Targeting the tumor microenvironment for cancer therapy. Clin. Chem., 2013, 59 (1), 85-93.
48. Polanska, U. M.; Orimo, A. Carcinoma-associated fibroblasts: nonneoplastic tumour-promoting mesenchymal cells. J. Cell Physiol., 2013, 228 (8), 1651-1657.
49. Ni, L.; Feng, Y.; Wan, H.; Ma, Q.; Fan, L.; Qian, Y.; Li, Q.; Xiang, Y.; Gao, B. Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol. Rep., 2012, 27 (3), 783-790.
50. Wen, S. W.; Ager, E. I.; Neo, J.; Christophi, C. The renin angiotensin system regulates Kupffer cells in colorectal liver metastases. Cancer Biol. Ther., 2013, 14 (8), 720-727.
51. Ager, E. I.; Neo, J.; Christophi, C. The renin-angiotensin system and malignancy. Carcinogenesis, 2008, 29 (9), 1675-1684.
52. Ager, E. I.; Wen, S. W.; Chan, J.; Chong, W. W.; Neo, J. H.; Christophi, C. Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation. BMC. Cancer, 2011, 11, 274.
53. Rodgers, K. E.; Oliver, J.; diZerega, G. S. Phase I/II dose escalation study of angiotensin 1-7 [A (1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother. Pharmacol., 2006, 57, 559-568.
54. Pham, H.; Schwartz, B. M.; Delmore, J. E.; Reed, E.; Cruickshank, S.; Drummond, L.; Rodgers, K. E.; Peterson, K. J.; diZerega, G. S. Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer Chemother. Pharmacol., 2013, 71 (4), 965-972.
55. Petty, W. J.; Miller, A. A.; McCoy, T. P.; Gallagher, P. E.; Tallant, E. A.; Torti, F. M. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin. Cancer Res., 2009, 15, 7398-7404.
56. Petty, W. J.; Aklilu, M.; Varela, V. A.; Lovato, J.; Savage, P. D.; Miller, A. A. Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1alpha in vascular sarcomas. BMC. Cancer, 2012, 12, 404.
57. Clark, M. A.; Tallant, E. A.; Diz, D. I. Downregulation of the AT1A receptor by pharmacologic concentrations of Angiotensin-(1-7). J. Cardiovasc. Pharmacol., 2001, 37 (4), 437-448. (Pubitemid 32240426)